Use access key #2 to skip to page content.
$43.22 -3.35 (-7.19%)
12/1/2008 4:07 PM

Quest Diagnostics, Inc. (DGX)

CAPS Rating:
*****

A provider of diagnostic testing, information and services, providing insights that enable physicians and other healthcare professionals to make decisions to improve health.

View Ticker Page (DGX)

Results 1 - 10 of 64 :   12345Next »

Recs

9

Avatar dm982 (< 20) Submitted: 10/04/06 11:53 AM : Outperform Start Price: $49.17 DGX Score: 26.56

Baby boomer population is getting old and I expect the lab testing to increase in the future (with Quest being the top dog)...I bought this in early Oct 2006 when there was a major drop in price (over 10%) with the news of the loss of the UnitedHealt...

Report this Post Replies: 1 | Reply | Permalink

Recs

5

Avatar Tony927 (< 20) Submitted: 8/29/06 11:08 PM : Outperform Start Price: $63.27 DGX Score: 5.56

DGX has a trailing PE of 22.3. That is a little higher than its average PE over the past year but not outrageous. It pays a dividend of 40 cents. It is the largest company of its type so it has economies of scale. It is in a relatively "safe" med...

Report this Post Replies: 1 | Reply | Permalink

Recs

4

Avatar killthebear (< 20) Submitted: 10/05/06 11:56 PM : Outperform Start Price: $51.86 DGX Score: 21.81

they did the right thing, accepting the UNH bid would have been a bigger burden than if they just let it go...their competitor will be drained by UNH and is trading at a premium to the DGX

Report this Post Replies: 0 | Reply | Permalink

Recs

3

Avatar hondo928 (99.85) Submitted: 11/29/07 3:28 PM : Outperform Start Price: $54.37 DGX Score: 23.36

This is like Charles River Labratories, a medical play that will always be in demand. 5 Year outperformer and probably more as these old folks start to retire and the hypochondriacs need more testing to make sure they don't die. And then their kids...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar c0ffeen0te (63.67) Submitted: 4/20/07 2:00 PM : Outperform Start Price: $49.37 DGX Score: 32.05

Market has rightly punished price for loss of customer, but valuation seems so low to me that given favorable demographics should be a good long term bet...fwiw, folks in the doctor's office i know greatly prefer their service to that of their compet...

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar overley (< 20) Submitted: 3/19/07 12:17 PM : Outperform Start Price: $48.63 DGX Score: 29.92

My doctor wants blood from me on a routine basis these days, and there is nothing physically wrong with me. Physicians are dependent upon diagnostic testing for nearly every condition, and new tests are developed every year. DGX is on sale @ 52 wk ...

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar NetscribeHealthC (59.02) Submitted: 1/30/07 7:20 AM : Outperform Start Price: $52.08 DGX Score: 25.31

Quest is the largest provider of diagnostic testing and information services, with nearly 25% market share, which include esoteric testing, gene-based testing, anatomic pathology services and testing for clinical trials. The company has a network of ...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar chk999longonly (84.45) Submitted: 2/24/08 12:53 PM : Outperform Start Price: $46.19 DGX Score: 33.00

This hit a 52 week low on the last trading day.

This is a play on the growing healthcare industry. As the boomers age, they will need more healthcare. This company does a lot of the lab tests that are becoming more important. This is looki...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar pickumnow (21.74) Submitted: 5/23/08 11:58 AM : Underperform Start Price: $49.15 DGX Score: -29.77

Good growth potential in an area that is need of productivity and quality care solutions.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar aitraders (< 20) Submitted: 1/31/08 2:26 PM : Outperform Start Price: $48.93 DGX Score: 28.36

Exorcised UNH, assimilated Ameripath, mid-year guidance of 6.1 to 6.2 B for 2007 will end up at 6.6/6.7, operating margins are going back up, Ameripath should fuel growth for 2008 and beyond, and now, I've read that the sales reps can now concentrate...

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links